CentoLCV™ – The New Standard for Detecting Chromosomal Imbalances
Watch Dr. Peter Bauer, MD, Chief Genomic Officer at CENTOGENE, as he discusses CentoLCV™, our comprehensive Large Copy number Variation (CNV) analysis, and why it is the new standard for establishing more accurate molecular diagnoses compared to conventional tests using microarrays.
Prof. Bauer speaks about the importance of copy number variation analysis in shortening the diagnostic odyssey and outlining the implementation of our latest detection platform that combines state-of-the-art genome sequencing technology and our extensive medical expertise. Throughout the webinar, he has provided examples of successful clinical cases ─ leading to better, more informed outcomes for patients suffering from recurrent genomic disorders and complex cases.
- Copy-number variation analysis as the status quo
- Using shallow whole genome sequencing to perform copy number variation analysis
- How CentoLCV™ performs in a clinical environment
- Successful application of CentoLCV™ in clinical cases
Dr. Peter Bauer, Chief Genomic Officer
Prof. Peter Bauer, MD, serves as CENTOGENE’s Chief Genomic Officer, where he combines clinical and medical understanding in genetic testing with an excellent knowledge of the latest scientific development, based on his extraordinary experience, especially in high-throughput genetic testing using next-generation sequencing.
Prof. Bauer received his board certification in Human Genetics in 2006 and headed the molecular diagnostic laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Additionally, he is Vice President of the German Society of Neurogenetics (DGNG). Peter has authored more than 140 publications in neurogenetics, oncogenetics, cardiogenetics, and sequencing technology.